RPRX — Royalty Pharma plc
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2020-06-16.
Performance
Technicals
Dividends
Measured signals that fired on RPRX
| date | signal | measured base rate |
|---|---|---|
| 2026-08-20 | Bollinger bandwidth breaks out of its own compression structure | -0.63% over 21 days · t = -2.80 · n = 7,196 statistically distinguishable from its control group |
| 2026-08-19 | Breakout to a 52-week high price | -1.00% over 21 days · t = -8.58 · n = 24,386 statistically distinguishable from its control group |
| 2026-08-18 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-07-17 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-07-13 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-07-09 | Bollinger bandwidth breaks out of its own compression structure | -0.63% over 21 days · t = -2.80 · n = 7,196 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-08-19 | Hite Christopher EVP & Chairman, Partnering | Gift 10b5-1 plan | 16.8K | 0.00 | 0 |
| 2026-08-18 | Hite Christopher EVP & Chairman, Partnering | Open-market sale 10b5-1 plan | 100.0K | 59.97 | 6.0M |
| 2026-08-13 | Coyne Terrance P. EVP & CFO | Open-market sale 10b5-1 plan | 9.2K | 58.59 | 540.8K |
| 2026-08-13 | Coyne Terrance P. EVP & CFO | Open-market sale 10b5-1 plan | 1.8K | 59.14 | 104.8K |
| 2026-08-05 | Hite Christopher EVP & Chairman, Partnering | Grant or award | 11.0K | 0.00 | 0 |
| 2026-08-05 | Legorreta Pablo G. CEO, Chairman of the Board | Grant or award | 65.2K | 0.00 | 0 |
| 2026-08-05 | Coyne Terrance P. EVP & CFO | Grant or award | 11.0K | 0.00 | 0 |
| 2026-08-05 | Urist Marshall EVP, Research & Investments | Grant or award | 8.3K | 0.00 | 0 |
| 2026-07-01 | Urist Marshall EVP, Research & Investments | Open-market sale 10b5-1 plan | 9.1K | 55.88 | 508.5K |
| 2026-06-30 | Hite Christopher EVP & Chairman, Partnering | Open-market sale 10b5-1 plan | 97.4K | 56.50 | 5.5M |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| MORGAN STANLEY | 2.1B | 43.6M |
| Capital International Investors | 1.7B | 35.0M |
| BlackRock, Inc. | 1.2B | 25.9M |
| FMR LLC | 1.2B | 25.2M |
| BAILLIE GIFFORD & CO | 775.0M | 16.2M |
| Swedbank AB | 555.8M | 11.6M |
| STATE STREET CORP | 527.2M | 11.0M |
| Capital World Investors | 385.5M | 8.0M |
| GEODE CAPITAL MANAGEMENT, LLC | 376.5M | 7.9M |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 358.8M | 7.5M |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Zealand gains $100M in funding from Royalty Pharma · 2026-08-12
- Royalty Pharma (RPRX) Q2 2026 Earnings Call Transcript · 2026-08-12
Others in Healthcare
Ask the AI about RPRX
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →